Veracyte Inc Stock News

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. William Blair 45th Annual Growth Stock Conference – Chicago, IL Presentation on June 3rd at 5:40 p.m. Eastern Time Jefferies Global Healthcare Conference – New York, NY Presentation on June 4th at 2:00 p.m. E...

Veracyte, Inc. (NASDAQ:VCYT ) Q1 2025 Earnings Call May 7, 2025 4:30 PM ET Company Participants Shayla Gorman - Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Chief Financial Officer John Leite - Chief Commercial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Andrew Brackmann - William Blair Puneet Souda - Leerink Partners Colleen Babingto...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the first quarter ended March 31, 2025. "We started 2025 with the eleventh consecutive quarter of 20% or more testing volume growth, driven by strong Decipher and Afirma demand,” said Marc Stapley, Veracyte's chief executive officer. “With soli...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing Will Be Presented at AUA Annual Meeting.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to National Cancer Institute's SEER Specialized Database Release.

A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer.